UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________

FORM 8-K

_________________________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 262, 2026

_________________________________

ALBEMARLE CORPORATION

(Exact name of registrant as specified in charter)

_________________________________

Virginia

001-12658

54-1692118

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4250 Congress Street, Suite 900

Charlotte, North Carolina 28209

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (980) 299-5700

Not applicable

(Former name or former address, if changed since last report.)

_________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a- 12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

COMMON STOCK, $.01 Par Value

ALB

New York Stock Exchange

DEPOSITARY SHARES, each representing a 1/20th interest in a share of 7.25% Series A Mandatory Convertible Preferred Stock

ALB PR A

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).


Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.0201 ~~Departure~~Completion of ~~Directors~~Acquisition or ~~Certain~~Disposition ~~Officers; Election~~ of ~~Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Assets.

~~(d)~~On ~~Effective~~March as2, of2026, ~~February~~Albemarle 26Corporation, ~~2026~~a Virginia corporation (the “Company” or “Albemarle”), completed the ~~Board~~previously announced sale of ~~Directors~~its 51% ownership interests (the “~~Board~~Sale”) ofin ~~Albemarle~~Ketjen Corporation, ~~(the~~a Delaware corporation (“~~Company~~Ketjen”), ~~appointed~~to ~~Ms.~~ChemCat ~~Michelle~~AcquisitionCo, T.LLC, ~~Collins~~a Delaware limited liability company organized by and ~~Mr.~~affiliated ~~Mark~~with R.KPS ~~Widmar~~Capital asPartners ~~independent~~LP, ~~members~~a New York based private equity firm. Ketjen’s business consists of ~~the~~developing, ~~Board~~manufacturing (including through toll manufacturing arrangements), and marketing catalysts and related products on a global basis.

~~Ms.~~In ~~Collins~~connection ~~has~~with ~~been~~the ~~appointed~~Sale, Albemarle expects to ~~the~~receive ~~Board’s~~an ~~Audit~~aggregate &amount ~~Finance~~of ~~Committee~~approximately ~~and~~$547 ~~Governance~~million &in ~~Public~~cash, ~~Policy~~inclusive ~~Committee.~~of ~~Mr.~~$22 ~~Widmar~~million ~~has~~in ~~been~~cash ~~appointed~~included towith Ketjen at the ~~Board’s~~time ~~Executive~~of ~~Compensation~~the &Sale. ~~Talent~~Together ~~Development~~with ~~Committee~~the ~~and~~sale ~~Safety~~of its 50% interest in the Eurecat joint venture to Axens SA, ~~Sustainability~~completed in January 2026, ~~Operations~~Albemarle’s &combined ~~Capital~~pre-tax ~~Committee~~proceeds for the two transactions total approximately $670 million.

InAt ~~accordance~~close ~~with~~of ~~our~~the ~~non-employee director compensation program~~Sale, ~~Ms.~~Albemarle ~~Collins~~retains ~~and~~a ~~Mr.~~49% ~~Widmar~~minority ~~will~~ownership ~~each~~interest ~~receive~~in anKetjen. ~~annual~~Albemarle ~~retainer~~also ofwill ~~$120,000,~~retain ~~payable~~100% ~~quarterly~~ownership ~~and pro-rated for partial quarter~~ of ~~appointment,~~Ketjen’s ~~and~~Performance anCatalyst ~~annual~~Solutions ~~grant of restricted stock equal to $170~~business,~~000~~ atwhich ~~the~~has ~~grant~~been ~~date,~~integrated ~~rounded~~into upAlbemarle’s toproduct ~~the nearest 25-share increment and pro-rated for partial year of appointment~~portfolio.

There is no arrangement or understanding with or between either of Ms. Collins or Mr. Widmar and any other persons pursuant to which they were selected as a director. There are no transactions in which either Ms. Collins or Mr. Widmar has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

On March 2, 2026, the Company issued a press release ~~announcing~~regarding the ~~appointments~~sale of its ownership interests in Ketjen, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and in Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall either be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific references in such a filing.

Item 98.01. ~~Financial~~Other ~~Statements and Exhibits~~Events.

On March 2, 2026, the Company issued a press release announcing the redemption of its 4.650% Senior Notes due 2027 and its offers to purchase for cash up to an aggregate purchase price of $500 million for (i) its 5.65% Senior Notes due 2052, (ii) its 5.45% Senior Notes due 2044, (iii) the 3.45% Senior Notes due 2029 of Albemarle Wodgina Pty Ltd, a wholly-owned subsidiary of the Company, and (iv) its 5.05% Senior Notes due 2032, upon the terms and subject to the conditions set forth in an Offer to Purchase, dated March 2, 2026.

A copy of the press release is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Exhibit
Exhibit
99.1	Press Release dated March 2, 2026, issued by the Company
Number		Exhibit
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
2.1		Stock Purchase Agreement, by and among Albemarle Corporation, Ketjen Corporation and ChemCat AcquisitionCo, LLC, dated as of October 25, 2025. [Filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K (No. 1-12658) filed on October 27, 2025, and incorporated herein by reference].
99.1*		Press release, dated March 2, 2026 issued by the Company.
99.2*		Press release, dated March 2, 2026 issued by the Company.
104*		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Included with this filing.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain information contained herein and in the exhibit hereto that are not statements of historical fact or current fact constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as “ambition” “anticipate,” “believe,” “estimate,” “expect,” ”goal” “guidance,” “intend,” “may,” “outlook,” and “scenario” “should,” “would,” “will” and similar references to future periods. Forward-looking statements may include statements regarding: approximate proceeds from the Sale and related transactions; the Company's plans to use proceeds from the Sale to fund the tender offers and redemption described herein; the anticipated completion of the tender offers and redemption of notes; and all other information relating to matters that are not historical facts. These and other forward-looking statements are based on management’s current estimates, assumptions and expectations and involve risks and uncertainties that could significantly affect expected results. Actual results could differ materially from those expressed or implied in the forward-looking statements if one or more of the underlying estimates, assumptions or expectations prove to be inaccurate or are unrealized. Factors that could cause Albemarle’s actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: changes in inflation or interest rates; volatility in the debt and equity market; changes in credit ratings; the Company’s ability to complete the tender offers on anticipated terms or at all; changes in economic and business conditions; changes in trade policies and tariffs; completion of the audit of our annual financial statements; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; geopolitical conflicts and political unrest; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under “Risk Factors” in Albemarle’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle’s website (investors.albemarle.com) and on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date of this Form 8-K. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALBEMARLE CORPORATION
Date: March 4, 2026	By:	/s/ Ander C. Krupa
Date: March 6, 2026	By:	/s/ Ander C. Krupa
		Ander C. Krupa
		General Counsel and Corporate Secretary

Filing Compare · ALBEMARLE CORP